Project Grant R21AI186385

Award Date 7/1/24
Completion Date 5/31/26
Dollars Obligated $418K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Sacramento, CA 95817, USA
Similar Awards
This Project Grant award of $290,132.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to define how the cellular protein Stem-Loop Binding Protein (SLBP) promotes the infectivity of Human Cytomegalovirus (HCMV). The research will: 1) Determine the function of SLBP required to enhance HCMV infectivity, 2) Characterize differences in the secretome (secreted factors) during HCMV infection with and without SLBP, and 3)...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $651,832.00 to The Children's Hospital of Philadelphia Research Institute. The funding supports research to understand how the Herpes Simplex Virus (HSV) manipulates the host cell's DNA damage response and proteome to promote viral gene expression and replication. The research team will utilize global proteomic...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Medical College of Wisconsin, Inc. (MCW) to study the impact of human cytomegalovirus (HCMV) infection on the development of human neural tissues. The $682,879 award, effective from January 24, 2025 to December 31, 2029, aims to: (1) define the transcriptional and cellular disruptions to developing human neural cells caused by...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), part of the Oral Diseases and Disorders Research program (CFDA 93.121), provides $1,337,014 to study the mechanisms by which the human Kaposi's sarcoma-associated herpesvirus (KSHV) manipulates cellular metabolism to facilitate viral replication and tumorigenesis. The key products and services to be delivered under this award include: 1) determining how KSHV's viral cyclin (vCyclin) hijacks the host...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $160,518 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Research Institute. The 5-year grant, which began on August 15, 2024, supports the development of the principal investigator into an independent researcher in the field of immune modulation cell therapy for critically ill children, particularly those who have undergone...
This federal Project Grant award of $489,500 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to improve the targeting and elimination of the intact HIV reservoir. The key products of this 2-year project conducted by The Children's Hospital of Philadelphia Research Institute are: Identifying distinct transcriptional, epigenetic, and clonal features of CD4+ T cells with intact...
This Project Grant award of $2,683,965.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will fund the development and optimization of an "all-human cellular system" for studying Alzheimer's disease (AD) and age-related dementias (ADRDs). The primary objectives are to: 1) define delivery conditions for introducing patient blood cells and plasma into a...
This Project Grant award of $178,000.00 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will support research to characterize the biogenesis and biological significance of protein phosphoribosylation in the context of herpes simplex virus 1 (HSV-1) infection. The research aims to: 1) identify and characterize the enzyme(s) that catalyze the ADP-ribosylation of the HSV-1 structural protein VP22, and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $658,273 to the University of Massachusetts Medical School to conduct research on how Herpes Simplex Virus 1 (HSV-1) interacts with and regulates the NLRP1 inflammasome pathway in human skin cells. The key goals are to: 1) Identify the mechanisms by which HSV-1 activates and inhibits the NLRP1 inflammasome, 2)...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to understand, prevent, and treat infections caused by herpes simplex viruses (HSV-1 and HSV-2). The $384,363 award to Temple University will fund a 5-year study to investigate the role of the Pellino1 (PELI1) protein in regulating antiviral immunity in skin keratinocytes and the epidermis. The research aims to provide insights...

STUDIES ON INHERITED CHROMOSOMALLY INTEGRATED HHV-6 WITH PATIENT-DERIVED INDUCED PLURIPOTENT STEM CELLS - PROJECT SUMMARY HUMAN HERPESVIRUS 6A AND HUMAN HERPESVIRUS 6B, COLLECTIVELY TERMED HHV-6A/B, ARE UBIQUITOUS VIRUSES THAT PERMANENTLY INFECT MOST HUMANS FROM AN EARLY AGE. INITIAL HHV-6A/B INFECTION MAINLY OCCURS FROM THE CONTACT OF INFECTED SALIVA OR NASAL MUCUS WITH THE RESPIRATORY TRACT. HOWEVER, HHV-6A/B GENOME CAN BE MAINTAINED GENERATION TO GENERATION THROUGH INHERITANCE, WHICH IS MEDIATED BY THE INTEGRATION OF HHV-6A/B GENOMES INTO THE TELOMERES OF HOST CELL CHROMOSOMES. INHERITED CHROMOSOMALLY INTEGRATED HUMAN HERPESVIRUS 6 (ICIHHV-6) IS SEEN IN 1-2% OF EUROPEAN AND US POPULATIONS AND 0.6% OF PEOPLE IN JAPAN. IN THESE HUMAN POPULATIONS, THE HHV-6 GENOME IS INTEGRATED INTO THE TELOMERE OF A SINGLE CHROMOSOME IN EVERY NUCLEATED CELL IN THE BODY. THESE INTEGRATED VIRUSES REACTIVATE FROM THE INTEGRATED CHROMOSOME TO PRODUCE VIRAL PROGENIES. REACTIVATION OF ICIHHV- 6 IS SUGGESTED TO BE ASSOCIATED WITH MANY DISEASE DEVELOPMENTS THAT INCLUDE ENCEPHALITIS, SPONTANEOUS ABORTIONS, PRE-ECLAMPSIA, ANGINA PECTORIS, AND EXACERBATION OF GRAFT-VERSUS-HOST DISEASE FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION. ACCUMULATING EVIDENCE HAS ALSO SUGGESTED THE NEUROVIRULENCE OF HHV- 6A/B INFECTION WITH SEVERAL IMPORTANT NEUROLOGICAL DISORDERS. IN PARTICULAR, EVIDENCE INDICATES THAT HHV-6B REACTIVATION CAN CAUSE ACUTE LIMBIC ENCEPHALITIS IN IMMUNOCOMPROMISED PATIENTS, AND FREQUENT VIRAL REACTIVATION CYCLES RESULT IN TEMPORAL LOBE EPILEPSY. HOWEVER, A LACK OF SUITABLE IN VITRO MODELS TO EVALUATE HHV-6A/B REACTIVATION FROM THE INTEGRATED VIRAL GENOME IN NEURAL CELLS, LIMITS OUR STUDY DESIGNS. THIS IS BECAUSE, FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM, THE AFFECTED TISSUE IS CHALLENGING TO ACCESS FOR STUDY IN LIVING PATIENTS. SUCH IN VITRO TISSUE CULTURE MODELS WILL EXAMINE RISKS OF HARBORING ICIHHV-6 IN DISEASE DEVELOPMENTS AND FACILITATE MOLECULAR ANALYSIS OF ICIHHV-6 REACTIVATION/REPLICATION FROM INTEGRATED HOST CHROMOSOMES. LIKE OTHER VIROLOGY RESEARCH, ESTABLISHING AN IN VITRO CULTURE MODEL IS VITAL TO IDENTIFY ESSENTIAL CELLULAR OR VIRAL TARGETS FOR FURTHER THERAPEUTIC DEVELOPMENT. HERE, WE REQUEST FUNDING TO ESTABLISH CELL MODELS TO STUDY ICIHHV-6 REACTIVATION. WE WILL GENERATE INDUCED PLURIPOTENT STEM CELLS (IPSCS) AND DIFFERENTIATE THEM INTO NEURAL STEM CELLS. WITH THE ESTABLISHED RESOURCES, WE WILL EXAMINE HOW AND WHEN ICIHHV-6 REACTIVATION IS TRIGGERED. WE WILL TEST WHAT PHYSIOLOGICAL CELL DIFFERENTIATION PROCESSES TRIGGER ICIHHV-6 REACTIVATION. WE WILL COMPLETE THE TASKS WITH ONGOING INTERNATIONAL COLLABORATION, AND DEVELOP ESSENTIAL RESOURCES FOR HHV-6A/B RESEARCHERS.

Posted 6/25/24, 12:00 AM